Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian G Feagan

Showing results (201-210 of 464) with videos related to

Pageof 47
Sort By:
Canadian Journal of Gastroenterology & Hepatology|February 17, 2025
Therapeutic Drug Monitoring for Dose Optimization of Infliximab in Patients With Inflammatory Bowel Disease: An Analysis of Canadian Real-World DataDavid C Sealey, Kai Fai Ho, Z Christina Zhou, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 1, 2024
Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With EtrasimodFernando Magro, Laurent Peyrin-Biroulet, Bruce E Sands, et al.
Annals of the Rheumatic Diseases|January 25, 2019
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trialsStefan Schreiber, Jean-Frederic Colombel, Brian G Feagan, et al.
Gastroenterology|September 27, 2013
Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitisBrian G Feagan, William J Sandborn, Andreas Lazar, et al.
Contemporary Clinical Trials|October 8, 2022
Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial programBrian G Feagan, Stefan Schreiber, Anita Afzali, et al.
Crohn'S & Colitis 360|February 13, 2023
Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative ColitisJaroslaw Kierkus, Marina Pesegova, Maria Klopocka, et al.
Crohn'S & Colitis 360|February 13, 2023
Corrigendum to: Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative ColitisJaroslaw Kierkus, Marina Pesegova, Maria Klopocka, et al.
Journal of Crohn'S & Colitis|April 9, 2025
Association of bile acid diarrhea with symptoms and disease activity in Crohn's disease: post-hoc clinical trial analysis of serum 7a-hydroxy-4cholestern-3-one, C4, in patients with active Crohn's diseaseRobert Battat, Soumya Kandi, Ana P Lacerda, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 6, 2020
Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative ColitisChristopher Ma, Jenny Jeyarajah, Leonardo Guizzetti, et al.
Gastroenterology|July 8, 2019
Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's DiseaseSilvio Danese, William J Sandborn, Jean-Frédéric Colombel, et al.
Pageof 47

Showing results (201-210 of 464) with videos related to

Sort By:
Pageof 47
Canadian Journal of Gastroenterology & Hepatology|February 17, 2025
Therapeutic Drug Monitoring for Dose Optimization of Infliximab in Patients With Inflammatory Bowel Disease: An Analysis of Canadian Real-World DataDavid C Sealey, Kai Fai Ho, Z Christina Zhou, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 1, 2024
Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With EtrasimodFernando Magro, Laurent Peyrin-Biroulet, Bruce E Sands, et al.
Annals of the Rheumatic Diseases|January 25, 2019
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trialsStefan Schreiber, Jean-Frederic Colombel, Brian G Feagan, et al.
Gastroenterology|September 27, 2013
Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitisBrian G Feagan, William J Sandborn, Andreas Lazar, et al.
Contemporary Clinical Trials|October 8, 2022
Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial programBrian G Feagan, Stefan Schreiber, Anita Afzali, et al.
Crohn'S & Colitis 360|February 13, 2023
Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative ColitisJaroslaw Kierkus, Marina Pesegova, Maria Klopocka, et al.
Crohn'S & Colitis 360|February 13, 2023
Corrigendum to: Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative ColitisJaroslaw Kierkus, Marina Pesegova, Maria Klopocka, et al.
Journal of Crohn'S & Colitis|April 9, 2025
Association of bile acid diarrhea with symptoms and disease activity in Crohn's disease: post-hoc clinical trial analysis of serum 7a-hydroxy-4cholestern-3-one, C4, in patients with active Crohn's diseaseRobert Battat, Soumya Kandi, Ana P Lacerda, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 6, 2020
Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative ColitisChristopher Ma, Jenny Jeyarajah, Leonardo Guizzetti, et al.
Gastroenterology|July 8, 2019
Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's DiseaseSilvio Danese, William J Sandborn, Jean-Frédéric Colombel, et al.
Pageof 47